Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Public ClinicalTrials.gov record NCT03232567. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age. Subjects will be screened within 28 days of randomization (Day 1).
Study identification
- NCT ID
- NCT03232567
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 49 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 17, 2017
- Primary completion
- Mar 6, 2018
- Completion
- Jun 14, 2018
- Last update posted
- Apr 29, 2024
2017 – 2018
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Optimal Health Research | Rockville | Maryland | 20850 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Influenza trials
Other public records listing Influenza. Sorted by last update posted; newest first. Not a recommendation.
- NCT07496450: A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults Active, not recruiting
- NCT07703514: Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates Not yet recruiting
- NCT06029933: Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years Recruiting
- NCT07215858: BPL-1357 Against H1N1 Influenza Virus Challenge Recruiting
- NCT04712539: Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients Recruiting
- NCT07149428: Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI) Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03232567, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2024 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03232567 live on ClinicalTrials.gov.